289 related articles for article (PubMed ID: 28324671)
21. Recombinant tissue plasminogen activator in the treatment of pleural infections in adults.
Froudarakis ME; Kouliatsis G; Steiropoulos P; Anevlavis S; Pataka A; Popidou M; Mikroulis D; Pneumatikos I; Bouros D
Respir Med; 2008 Dec; 102(12):1694-700. PubMed ID: 18824340
[TBL] [Abstract][Full Text] [Related]
22. Alteplase and DNase for the treatment of pleural empyema in rats.
Gehlen M; Fraga JC; Amantea SL; Silveira NP; Kulczynski J; Roesch E; Portal KG; Sanches PR
Pulm Pharmacol Ther; 2019 Apr; 55():1-4. PubMed ID: 30648619
[TBL] [Abstract][Full Text] [Related]
23. Rethinking the Doses of Tissue Plasminogen Activator and Deoxyribonuclease Administrated Concurrently for Intrapleural Therapy for Complicated Pleural Effusion and Empyema.
Innabi A; Surana A; Alzghoul B; Meena N
Cureus; 2018 Feb; 10(2):e2214. PubMed ID: 30755840
[TBL] [Abstract][Full Text] [Related]
24. Intrapleural alteplase in a patient with complicated pleural effusion.
Walker CA; Shirk MB; Tschampel MM; Visconti JA
Ann Pharmacother; 2003 Mar; 37(3):376-9. PubMed ID: 12639166
[TBL] [Abstract][Full Text] [Related]
25. Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients.
Kanellakis NI; Wrightson JM; Hallifax R; Bedawi EO; Mercer R; Hassan M; Asciak R; Hedley E; Dobson M; Dong T; Psallidas I; Rahman NM
BMJ Open Respir Res; 2019; 6(1):e000440. PubMed ID: 31673364
[TBL] [Abstract][Full Text] [Related]
26. Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial.
Livingston MH; Mahant S; Ratjen F; Connolly BL; Thorpe K; Mamdani M; Maclusky I; Laberge S; Giglia L; Walton JM; Yang CL; Roberts A; Shawyer AC; Brindle M; Parsons SJ; Stoian CA; Cohen E
Trials; 2017 Jun; 18(1):293. PubMed ID: 28646887
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy and bleeding outcomes of tissue plasminogen activator and dornase alfa in pleural space infection with once daily concurrent administration: a retrospective cohort study.
Jiang C; Xie M; Cervellione K; Thurm C
BMC Res Notes; 2020 Aug; 13(1):368. PubMed ID: 32746902
[TBL] [Abstract][Full Text] [Related]
28. Intrapleural use of tissue plasminogen activator and DNase in pleural infection.
Rahman NM; Maskell NA; West A; Teoh R; Arnold A; Mackinlay C; Peckham D; Davies CW; Ali N; Kinnear W; Bentley A; Kahan BC; Wrightson JM; Davies HE; Hooper CE; Lee YC; Hedley EL; Crosthwaite N; Choo L; Helm EJ; Gleeson FV; Nunn AJ; Davies RJ
N Engl J Med; 2011 Aug; 365(6):518-26. PubMed ID: 21830966
[TBL] [Abstract][Full Text] [Related]
29. Intrapleural alteplase decreases parapneumonic effusion volume in children more than saline irrigation.
Hanson SJ; Havens PL; Simpson PM; Nugent ML; Wells RG
Pediatr Pulmonol; 2015 Dec; 50(12):1328-35. PubMed ID: 25847131
[TBL] [Abstract][Full Text] [Related]
30. Tissue plasminogen activator combined with human recombinant deoxyribonuclease is effective therapy for empyema in a rabbit model.
Zhu Z; Hawthorne ML; Guo Y; Drake W; Bilaceroglu S; Misra HL; Light RW
Chest; 2006 Jun; 129(6):1577-83. PubMed ID: 16778278
[TBL] [Abstract][Full Text] [Related]
31. Stratifying fibrinolytic dosing in pediatric parapneumonic effusion based on ultrasound grade correlation.
James CA; Braswell LE; Pezeshkmehr AH; Roberson PK; Parks JA; Moore MB
Pediatr Radiol; 2017 Jan; 47(1):89-95. PubMed ID: 27709281
[TBL] [Abstract][Full Text] [Related]
32. Intrapleural fibrinolysis for parapneumonic effusion and empyema in children.
Wells RG; Havens PL
Radiology; 2003 Aug; 228(2):370-8. PubMed ID: 12893898
[TBL] [Abstract][Full Text] [Related]
33. An international survey on the use of intrapleural tissue plasminogen activator/DNase therapy for pleural infection.
Lau EPM; Eshraghi M; Dootson K; Yeoh C; Ywe Phu W; Lee YCG; Popowicz ND
ERJ Open Res; 2022 Jan; 8(1):. PubMed ID: 35141321
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of intrapleural instillation of alteplase in the management of complicated pleural effusion or empyema.
Thommi G; Nair CK; Aronow WS; Shehan C; Meyers P; McLeay M
Am J Ther; 2007; 14(4):341-5. PubMed ID: 17667208
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safety of tissue plasminogen activator in the management of complicated parapneumonic effusions.
Weinstein M; Restrepo R; Chait PG; Connolly B; Temple M; Macarthur C
Pediatrics; 2004 Mar; 113(3 Pt 1):e182-5. PubMed ID: 14993574
[TBL] [Abstract][Full Text] [Related]
36. Choice of intrapleural fibrinolytic agents in the treatment of adult complicated parapneumonic effusion and empyema: Network meta-analysis.
Yokoyama Y; Kuno T; Takagi H; Burfeind W
Asian Cardiovasc Thorac Ann; 2023 Jun; 31(5):451-458. PubMed ID: 37287257
[TBL] [Abstract][Full Text] [Related]
37. Intrapleural tissue plasminogen activator for complicated pleural effusions.
Skeete DA; Rutherford EJ; Schlidt SA; Abrams JE; Parker LA; Rich PB
J Trauma; 2004 Dec; 57(6):1178-83. PubMed ID: 15625447
[TBL] [Abstract][Full Text] [Related]
38. Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models.
Komissarov AA; Florova G; Azghani AO; Buchanan A; Boren J; Allen T; Rahman NM; Koenig K; Chamiso M; Karandashova S; Henry J; Idell S
Am J Physiol Lung Cell Mol Physiol; 2016 Aug; 311(2):L389-99. PubMed ID: 27343192
[TBL] [Abstract][Full Text] [Related]
39. Intrapleural Fibrinolytic Therapy versus Early Medical Thoracoscopy for Treatment of Pleural Infection. Randomized Controlled Clinical Trial.
Kheir F; Thakore S; Mehta H; Jantz M; Parikh M; Chee A; Kaphle U; Sisnega C; Fernandez-Bussy S; Majid A
Ann Am Thorac Soc; 2020 Aug; 17(8):958-964. PubMed ID: 32421353
[No Abstract] [Full Text] [Related]
40. Successful management of pleural infection with very low dose intrapleural tissue plasminogen activator/deoxyribonuclease regime.
Hart JA; Badiei A; Lee YCG
Respirol Case Rep; 2019 Apr; 7(3):e00408. PubMed ID: 30805192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
